



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 07 Mar 2022 (#9)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

- **Financial Conflict of Interest: All Principal Investigators (PIs) and Key Personnel (KP) of all current NIH grants, direct and subawards, must complete the NIH training and submit the certificate the Grants Management Office) not later than 31 March 2022.** For all new applications, all PI's & KP must complete the certificate before the application can be submitted to NIH. This is in addition to the FCOI declarations that must be signed.
 - FHMS contact: cdevries@sun.ac.za
 - Stellenbosch Campus contact lizelk@sun.ac.za.

Link to the training: https://grants.nih.gov/grants/policy/coi/tutorial2018/story_html5.html

- **[NOT-OD-21-110](#) Implementation of Changes to the Biographical Sketch and Other Support Format Page.** This notice describes implementation of the updated Other Support and Biosketch format pages and associated instructions, as outlined in [NOT-OD-21-073](#). **ScienCV:** <https://www.ncbi.nlm.nih.gov/sciencv/>
- **[NOT-RM-22-007](#) Notice of Intent to Publish a Funding Opportunity Announcement for Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allowed).** The Somatic Cell Genome Editing (SCGE) program from the NIH Common Fund intends to issue Funding Opportunity Announcements (FOAs) for the second phase (FY2023-2027) of the program. In Phase 2 the SCGE program will accelerate the development of genome editing therapeutic agents by: facilitating Investigational New Drug (IND) application enabling studies; establishing pathways to regulatory approval; and disseminating successful strategies for initiating first in human clinical trials. SCGE Phase 2 will include four FOAs: 1) an initiative for the development of technology/assays that support IND-submissions, 2) another for optimizing genome editing-based therapeutic leads for safety and efficacy, 3) a platform clinical trials initiative using genome editing therapeutics for more than one disease, 4) and a Translational Coordination and Dissemination Center (TCDC). Together these initiatives will comprise a consortium that will accelerate the optimization of promising clinical candidates toward IND filings and first in human clinical trials. This Notice is being provided to allow potential applicants sufficient time to develop responsive projects.
- **[NOT-TR-22-016](#) Notice of Intent to Publish a Funding Opportunity Announcement for Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U2C Clinical Trial Not Allowed)** The National Center for Advancing Translational Sciences (NCATS) intends to publish a Funding Opportunity Announcement (FOA) to advance the diagnosis, management, and treatment of rare diseases). The Rare Diseases Clinical Research Network (RDCRN) consists of the Rare Diseases Clinical Research Consortia (RDCRC) that promote highly collaborative, multi-site, patient-centric, translational, and clinical research and the Data Management and Coordinating Center (DMCC), which will facilitate and support the activities of each of the Rare Diseases Clinical Research Consortia (RDCRC) along with trans-network activities

that broadly facilitate the advancement of rare disease research. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

- [NOT-AI-22-035](#) **Pre-Solicitation Notice: Resources to Advance Pediatrics and HIV Prevention Science (RAPPS), RFP: 75N93021R00020.** As a resource to the fields of HIV treatment and prevention, NIAID maintains contracts to support the development of emerging HIV therapeutics, vaccines, and nBP candidates. The services under these contracts are provided on a case-by-case basis and are designed to assist in filling key gaps in their product development pathway. These services have enabled the acquisition of critical data, development of essential methods, manufacture and characterization of products, fulfillment of regulatory requirements, and/or completion of studies necessary for entering clinical trials. Over the past years, these contract activities have helped investigators to obtain critical data and materials to attract additional funding, gain prospective partnership, fulfil regulatory requirements, and complete studies before entering clinical trials. Information about these contract resources or activities can be found at the following website: <https://www.niaid.nih.gov/research/resources>.

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notices of Special Interest

- [NOT-DA-23-006](#) **Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance Use Prevention and Treatment.** This Notice encourages research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment, 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, social media, and mortality records). Collaborations among multiple disciplines are encouraged for this Notice. Priority will be given to applications that demonstrate the involvement and support of community-based stakeholders and other end-users (e.g., clinicians, patients, parents, public health professionals, patient representatives) along the research continuum.

Funding Opportunity Announcements (FOA)

1. Improved Drug Susceptibility Testing (DST) for Tuberculosis (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-22-016](#)

Type: R01

Application Due Date: July 08, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support the development of new diagnostic technologies for tuberculosis (TB) drug susceptibility testing (DST), including point of care (POC) DST and companion diagnostics for new TB drugs.

Budget: NIAID intends to commit \$3 million in FY 2023 to fund 4-6 awards. Application budgets are limited to no more than \$500,000 in direct costs for any project year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Partnerships for Rapid Diagnostics and Phenotypic Antibacterial Susceptibility Testing for Bacteremia or Hospital Acquired Pneumonia (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** [RFA-AI-22-010](#) **Type:** R01

Application Due Date: June 01, 2022 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support research projects focused on development and/or production of medical diagnostics that permit rapid differential species identification, and corresponding phenotypic antibacterial susceptibility profiles for bacteremia or hospital acquired pneumonia. The primary goal of such diagnostics is to facilitate antibacterial stewardship, thereby reducing selective pressure and improving patient outcomes.

Budget: NIAID intends to commit \$4.8 million in FY2023 to fund 5-7 awards. Recommended budgets for direct costs of up to \$500,000 per year may be requested. Applicants may also request up to an additional \$150,000 in the first year of the award for major, essential equipment to ensure that research objectives can be met, totalling \$650,000 direct costs for Year 1 only. The scope of the proposed project should determine the project period. The maximum project period is 5 years

3. NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** [PAR-22-128](#) **Type:** R34

Application Due Date: July 16, 2022 through to May 07, 2025. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NEI supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This clinical research planning grant funding opportunity supports applicants in their planning efforts to conduct collaborative clinical research. The grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.

Budget: The NEI permits direct costs up to \$150,000 per year plus applicable F&A for consortia. The scope of the proposed project should determine the project period. The maximum period is two years.

4. Noncoding RNAs in Alzheimer's Disease and Related Dementias (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** [RFA-AG-23-010](#) **Type:** R01

Application Due Date: July 15, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The goal of this Funding Opportunity Announcement (FOA) is to stimulate research in noncoding RNAs (ncRNAs) to investigate the causality, directionality, mechanisms, and therapeutic potential of ncRNAs in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This FOA supports applications seeking to discover novel mechanisms mediated by ncRNAs and to elucidate molecular and cellular functions involved in the pathogenesis and progression of AD/ADRD.

Companion Funding: [RFA-AG-23-011](#), [R21](#) Exploratory/Developmental Grants

Budget: NIA intends to commit \$5 million in FY 2023 to support up to 10 awards. Application budgets need to reflect the actual needs of the proposed project and should be limited to no more than \$500,000 in direct costs per year. The maximum project period is five years.

5. Biosimilar User Fee Act (BsUFA) Research Grant (U01) Clinical Trials Optional

Letter of Intent: 30 days prior to the application due date **Hyperlink:** [RFA-FD-22-026](#) **Type:** U01

Application Due Date: May 9, 2022, by 11:59 PM Eastern Time.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support research projects that enhance biosimilar and interchangeable biological product development and regulatory science.

Budget: FDA/CDER intends to commit up to \$5 million, in FY 2022 in support of this grant program. It is anticipated that up to five (5) awards will be made, not to exceed \$1 million in total costs (direct plus indirect), per award per year.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krottoa Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105